{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T14:49:39Z","timestamp":1773067779316,"version":"3.50.1"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,1,1]],"date-time":"2015-01-01T00:00:00Z","timestamp":1420070400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,7,22]],"date-time":"2013-07-22T00:00:00Z","timestamp":1374451200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Saudi Pharmaceutical Journal"],"published-print":{"date-parts":[[2015,1]]},"DOI":"10.1016\/j.jsps.2013.06.003","type":"journal-article","created":{"date-parts":[[2013,6,27]],"date-time":"2013-06-27T04:06:08Z","timestamp":1372305968000},"page":"9-13","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"title":["Importance and globalization status of good manufacturing practice (GMP) requirements for pharmaceutical excipients"],"prefix":"10.1007","volume":"23","author":[{"given":"Abubaker","family":"Abdellah","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed Ibrahim","family":"Noordin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wan Azman","family":"Wan Ismail","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"10.1016\/j.jsps.2013.06.003_b0005","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1057\/9780230372597_4","article-title":"Globalization of medicines control","volume":"54","author":"Abraham","year":"2003","journal-title":"Regulation of the Pharmaceutical Industry"},{"issue":"6","key":"10.1016\/j.jsps.2013.06.003_b0010","first-page":"591","article-title":"Directly compressible adjuvants \u2013 a pharmaceutical approach","volume":"56","author":"Ahjel","year":"2008","journal-title":"Farmacia"},{"issue":"11","key":"10.1016\/j.jsps.2013.06.003_b0015","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1002\/jps.10154","article-title":"Excipient \u2013 drug interactions in parenteral formulations","volume":"91","author":"Akers","year":"2002","journal-title":"Journal of Pharmaceutical Sciences"},{"key":"10.1016\/j.jsps.2013.06.003_b0020","first-page":"259","article-title":"Globalization and the nation-state: an appraisal of the discussion","author":"Alasuutari","year":"2000","journal-title":"Acta Sociologica"},{"key":"10.1016\/j.jsps.2013.06.003_b0025","article-title":"Emerging excipients in parenteral medications","author":"Apte","year":"2003","journal-title":"Pharmaceutical Technology"},{"issue":"2","key":"10.1016\/j.jsps.2013.06.003_b0030","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1006\/rtph.2000.1421","article-title":"Pharmaceutical excipient development: the need for preclinical guidance","volume":"32","author":"Baldrick","year":"2000","journal-title":"Regulatory Toxicology and Pharmacology"},{"issue":"3","key":"10.1016\/j.jsps.2013.06.003_b0035","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.yrtph.2009.09.015","article-title":"The safety of chitosan as a pharmaceutical excipient","volume":"56","author":"Baldrick","year":"2010","journal-title":"Regulatory Toxicology and Pharmacology"},{"issue":"7","key":"10.1016\/j.jsps.2013.06.003_b0160","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.addr.2007.05.012","article-title":"Cyclodextrins as pharmaceutical solubilizers","volume":"59","author":"Brewster","year":"2007","journal-title":"Advanced drug delivery reviews"},{"key":"10.1016\/j.jsps.2013.06.003_b0040","unstructured":"Chow, F., Davidson, J. et al. 2009. An effective quality system approach for the qualification of excipient suppliers."},{"issue":"2","key":"10.1016\/j.jsps.2013.06.003_b0045","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.healthpol.2009.11.019","article-title":"A survey exploring knowledge and perceptions of general practitioners towards the use of generic medicines in the northern state of Malaysia","volume":"95","author":"Chua","year":"2010","journal-title":"Health Policy"},{"issue":"2","key":"10.1016\/j.jsps.2013.06.003_b0050","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1002\/hpm.698","article-title":"Globalization, global health, and access to healthcare","volume":"18","author":"Collins","year":"2003","journal-title":"The International Journal of Health Planning and Management"},{"issue":"1","key":"10.1016\/j.jsps.2013.06.003_b0165","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.ijpharm.2004.03.001","article-title":"Impact of excipients on the absorption of P-glycoprotein substrates in vitro and in vivo","volume":"278","author":"Cornaire","year":"2004","journal-title":"International journal of pharmaceutics"},{"key":"10.1016\/j.jsps.2013.06.003_b0055","first-page":"7","article-title":"Drug-excipient interactions","volume":"4","author":"Crowley","year":"2001","journal-title":"Pharmacy Technology"},{"key":"10.1016\/j.jsps.2013.06.003_b0060","first-page":"1","article-title":"Pharmaceutical excipients-the past and future","author":"Ermens","year":"2004","journal-title":"Business Briefing: Pharmagenerics"},{"issue":"1","key":"10.1016\/j.jsps.2013.06.003_b0170","first-page":"76","article-title":"A review of co-processed directly compressible excipients","volume":"8","author":"Gohel","year":"2005","journal-title":"J Pharm Pharm Sci"},{"issue":"2","key":"10.1016\/j.jsps.2013.06.003_b0175","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1007\/BF03259937","article-title":"Pharmaceutical excipients. Adverse effects associated with inactive ingredients in drug products (Part I)","volume":"3","author":"Golightly","year":"1988","journal-title":"Medical toxicology and adverse drug experience"},{"key":"10.1016\/j.jsps.2013.06.003_b0065","unstructured":"Guideline, I. C. H. H. T. (2009). Pharmaceutical development. Q8. Current Step 4."},{"issue":"9","key":"10.1016\/j.jsps.2013.06.003_b0070","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1023\/A:1011929016601","article-title":"Chitosan and its use as a pharmaceutical excipient","volume":"15","author":"Ilium","year":"1998","journal-title":"Pharmaceutical Research"},{"issue":"10","key":"10.1016\/j.jsps.2013.06.003_b0075","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/S1461-5347(00)00301-1","article-title":"Drug \u2013 excipient interactions and their affect on absorption","volume":"3","author":"Jackson","year":"2000","journal-title":"Pharmaceutical Science & Technology Today"},{"issue":"2","key":"10.1016\/j.jsps.2013.06.003_b0080","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/S1461-5347(99)00237-0","article-title":"An overview of the different excipients useful for the direct compression of tablets","volume":"3","author":"Jivraj","year":"2000","journal-title":"Pharmaceutical Science & Technology Today"},{"issue":"3","key":"10.1016\/j.jsps.2013.06.003_b0085","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.ejpb.2003.12.006","article-title":"Effect of N-methyl-2-pyrrolidone on skin permeation of estradiol","volume":"57","author":"Koizumi","year":"2004","journal-title":"European Journal of Pharmaceutics and Biopharmaceutics"},{"issue":"1","key":"10.1016\/j.jsps.2013.06.003_b0180","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1002\/jps.2600620107","article-title":"A new tablet disintegrating agent: Cross-linked polyvinylpyrrolidone","volume":"62","author":"Kornblum","year":"1973","journal-title":"Journal of pharmaceutical sciences"},{"key":"10.1016\/j.jsps.2013.06.003_b0090","first-page":"86","article-title":"Pharmaceutical excipient testing and control strategies","author":"Larner","year":"2006","journal-title":"Pharmaceutical Technology"},{"issue":"2","key":"10.1016\/j.jsps.2013.06.003_b0185","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1136\/ejhpharm-2012-000074.372","article-title":"Hospitalised Estonian newborns are exposed to a significant amount of potentially toxic excipients","volume":"19","author":"Lass","year":"2012","journal-title":"European Journal of Hospital Pharmacy: Science and Practice"},{"issue":"5","key":"10.1016\/j.jsps.2013.06.003_b0095","article-title":"Raising expectations of excipients","volume":"28","author":"Monsuur","year":"2010","journal-title":"Chimica oggi"},{"issue":"10","key":"10.1016\/j.jsps.2013.06.003_b0100","first-page":"4","article-title":"Functionality and Performance of Excipients","volume":"30","author":"Moreton","year":"2006","journal-title":"Pharmaceutical Technology"},{"issue":"5","key":"10.1016\/j.jsps.2013.06.003_b0190","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1177\/109158180302200507","article-title":"Toxicity of excipients\u2014A Food and Drug Administration perspective","volume":"22","author":"Osterberg","year":"2003","journal-title":"International Journal of Toxicology"},{"issue":"8","key":"10.1016\/j.jsps.2013.06.003_b0105","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S0014-827X(03)00079-X","article-title":"The safety of pharmaceutical excipients","volume":"58","author":"Pifferi","year":"2003","journal-title":"Il Farmaco"},{"issue":"1\u20132","key":"10.1016\/j.jsps.2013.06.003_b0110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0014-827X(98)00101-3","article-title":"Quality and functionality of excipients","volume":"54","author":"Pifferi","year":"1999","journal-title":"Il Farmaco"},{"issue":"1","key":"10.1016\/j.jsps.2013.06.003_b0115","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0014-827X(98)00101-3","article-title":"Quality and functionality of excipients","volume":"54","author":"Pifferi","year":"1999","journal-title":"Il Farmaco"},{"key":"10.1016\/j.jsps.2013.06.003_b0120","unstructured":"Rafidison, P., Ulman K., 2003. Critical good manufacturing practice aspects to consider for pharmaceutical excipients. Available from: www.touchhealthsciences.com"},{"issue":"2","key":"10.1016\/j.jsps.2013.06.003_b0125","first-page":"33","article-title":"Tools to ensure safe medicines: new monograph tests in USP-NF","volume":"1","author":"Sheehan","year":"2010","journal-title":"Journal of Excipients and Food Chemicals"},{"key":"10.1016\/j.jsps.2013.06.003_b0130","article-title":"Globalization: is it good or bad","volume":"23","author":"Srinivasan","year":"2002","journal-title":"Economic Policy Brief"},{"issue":"7","key":"10.1016\/j.jsps.2013.06.003_b0195","first-page":"62","article-title":"From inactive ingredients to pharmaceutical excipients","volume":"25","author":"Steinberg","year":"2001","journal-title":"Pharmaceutical Technology"},{"issue":"2","key":"10.1016\/j.jsps.2013.06.003_b0135","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1023\/B:PHAM.0000016235.32639.23","article-title":"Solubilizing excipients in oral and injectable formulations","volume":"21","author":"Strickley","year":"2004","journal-title":"Pharmaceutical Research"},{"key":"10.1016\/j.jsps.2013.06.003_b0140","unstructured":"U.S. Department of Health and Human Services, F. a. D. A., Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research BER) (2006). Guidance for Industry Q8 Pharmaceutical Development. Q8, ICH."},{"issue":"1","key":"10.1016\/j.jsps.2013.06.003_b0145","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1002\/jps.20726","article-title":"Evaluation of hydroperoxides in common pharmaceutical excipients","volume":"96","author":"Wasylaschuk","year":"2007","journal-title":"Journal of Pharmaceutical Sciences"},{"key":"10.1016\/j.jsps.2013.06.003_b0150","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1177\/009286159703100332","article-title":"Globalization and harmonization of regulatory issues: the WHO perspective of developing countries\u2019 needs and perspectives","volume":"31","author":"Wehrli","year":"1997","journal-title":"Drug Information Journal"},{"issue":"3","key":"10.1016\/j.jsps.2013.06.003_b0155","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1038\/sj.clpt.6100493","article-title":"The effect of globalization of drug manufacturing, production, and sourcing and challenges for American drug safety","volume":"83","author":"Woo","year":"2008","journal-title":"Clinical Pharmacology & Therapeutics"}],"container-title":["Saudi Pharmaceutical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1319016413000753?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1319016413000753?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T17:28:43Z","timestamp":1736184523000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1319016413000753"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,1]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,1]]}},"alternative-id":["S1319016413000753"],"URL":"https:\/\/doi.org\/10.1016\/j.jsps.2013.06.003","relation":{},"ISSN":["1319-0164"],"issn-type":[{"value":"1319-0164","type":"print"}],"subject":[],"published":{"date-parts":[[2015,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Importance and globalization status of good manufacturing practice (GMP) requirements for pharmaceutical excipients","name":"articletitle","label":"Article Title"},{"value":"Saudi Pharmaceutical Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jsps.2013.06.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Production and hosting by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}